Managing Cancer Cachexia
E. Fabbro, A. Inui, F. Strasser
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
The European Palliative Care Research Collaboration (EPCRC) has developed evidence-based recommendations for the classification and treatment of cachexia in advanced cancer patients . These treatment guidelines focus on patients with advanced cancer that are likely to suffer from refractory cachexia, a very serious condition especially as many of these patients are receiving palliative care and life expectancy is often short. Little cachexia-specific research has been done on this patient group and the EPCRC treatment guidelines had to consider whether research results taken from other disease stages could be applicable for patients with advanced and incurable disease with refractory cachexia .
This paper references
Ghrelin Inhibits Proinflammatory Responses and Nuclear Factor-κB Activation in Human Endothelial Cells
W. Li (2004)
Cachexia and Wasting: A Modern Approach
G. Mantovani (2006)
Cancer wasting and quality of life react to early individualized nutritional counselling!
P. Ravasco (2007)
Anorexia/cachexia‐related quality of life for children with cancer
J. Lai (2005)
The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials
R. Wit (2004)
Nutritional status of elderly patients during recovery from chest infection and the role of nutritional supplementation assessed by a prospective randomized single-blind trial.
J. Woo (1994)
Are all 5-HT3 receptor antagonists the same?
Robert M McNulty (2007)
Cancer Cachexia: Traditional Therapies and Novel Molecular Mechanism-Based Approaches to Treatment
N. Kumar (2010)
Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells.
V. Dixit (2004)
Cracking the riddle of cancer anorexia.
A. Laviano (1996)
Body-composition changes in patients who gain weight while receiving megestrol acetate.
C. Loprinzi (1993)
Benefits of supplementary tube feeding after fractured neck of femur: a randomised controlled trial.
M. Bastow (1983)
Megestrol acetate in cancer anorexia and weight loss
N. S. Tchekmedyian (1992)
Exercise, Cachexia, and Cancer Therapy: A Molecular Rationale
C. Ardies (2002)
Predictors of 2-year mortality among older male veterans on a geriatric rehabilitation unit.
C. McMurtry (1995)
Hypothalamic dopamine and serotonin in the regulation of food intake.
M. Meguid (2000)
Cancer cachexia: developing multimodal therapy for a multidimensional problem.
K. Fearon (2008)
Cachexia, malnutrition, the refeeding syndrome, and lessons from Goldilocks.
J. Palesty (2011)
Pharmacologic management of anorexia/cachexia.
F. Ottery (1998)
Failure to thrive.
C. Jolley (2003)
Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.
F. Roila (1991)
Basics in Clinical Nutrition
L. Sobotka (2004)
A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome
C. Moertel (1991)
Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.
C. Loprinzi (1993)
Treatment of cancer anorexia with megestrol acetate: which is the optimal dose?
J. Feliu (1991)
Pharmacology of cannabinoid CB1 and CB2 receptors.
R. Pertwee (1997)
Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways.
Talat Waseem (2008)
Pharmacotherapy of Cachexia
J. R. Nicholson (2005)
Effects of cyproheptadine clorhydrate ,a serotonin receptor antagonist ,on endocrine parameters in weight-loss related amenorrhea
A. Genazzani (2001)
The role of nutrition in increased morbidity and mortality.
D. Sullivan (1995)
Hematopoietic growth factors in the older cancer patient.
L. Balducci (2001)
Primary care of the patient with cancer.
G. F. Smith (2007)
Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats.
R. Wu (2007)
Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.
K. Rowland (1996)
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
P. Hesketh (2003)
Cancer cachexia: pathophysiologic aspects and treatment options.
E. Topkan (2007)
Serotonin antagonists: a new class of antiemetic agents.
P. Hesketh (1991)
Cancer-Induced Fatigue and Skeletal Muscle Wasting: The Role of Exercise
S. Al-Majid (2001)
Importance of nausea
K. Jenns (1994)
Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist
P. Eisenberg (2003)
Assessment of growth.
T. J. Cole (2002)
A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia
J. M. García (2007)
Therapeutic action of ghrelin in a mouse model of colitis.
E. Gónzalez-Rey (2006)
The starving patient: supportive care for people with cancer.
Whitman Mm (2000)
Cancer cachexia: a therapeutic approach.
J. Argilés (2001)
Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis
S. Grunberg (2003)
High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials.
M. Maltoni (2001)
The refeeding syndrome: a review.
S. Solomon (1990)
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.
C. Loprinzi (1990)
Malnutrition in childhood cancer patients: a review on its prevalence and possible causes.
A. Brinksma (2012)
A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer
E. Bruera (1990)
Eating-related disorders in patients with advanced cancer
F. Strasser (2002)
A Phase II Study of Delta-9-Tetrahydrocannabinol for Appetite Stimulation in Cancer-Associated Anorexia
K. Nelson (1994)
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.
G. Bodey (1966)
A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia
Carl G. Kardinal (1990)
Refeeding Syndrome: A Literature Review
L. R. Khan (2011)
Impact of nutritional status on health outcomes of nursing home residents.
D. Sullivan (1995)
Nutritional management in long-term care: development of a clinical guideline. Council for Nutritional Strategies in Long-Term Care.
D. R. Thomas (2000)
Symptom control in palliative care--Part II: cachexia/anorexia and fatigue.
E. Del Fabbro (2006)
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
P. Hesketh (1997)
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.
G. Mantovani (2010)
The cancer anorexia-cachexia syndrome.
K. Nelson (1994)
Failure to Thrive
W. Wilcox (1989)
Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial
K. Fearon (2003)
Managing Cancer-Related Anorexia/Cachexia
G. Mantovani (2012)
Ghrelin for cachexia
T. Akamizu (2010)
Cancer Anorexia‐Cachexia Syndrome: Current Issues in Research and Management
A. Inui (2002)
Treatment of Cachexia in Oncology
EM Tazi (2010)
Ghrelin: An orexigenic and somatotrophic signal from the stomach
A. Inui (2001)
Antiemetic guidelines: creating a more practical treatment approach
J. Koeller (2001)
Protein-energy undernutrition and the risk of mortality within one year of hospital discharge: a follow-up study.
D. Sullivan (1995)
Cancer cachexia syndrome in head and neck cancer patients: Part I. Diagnosis, impact on quality of life and survival, and treatment
M. Couch (2007)
Treatment of Cachexia in the Elderly
S. Yeh (2006)
Recent clinical experience with dronabinol
T. Plasse (1991)
A chart review of cyproheptadine for stimulant-induced weight loss.
W. B. Daviss (2004)
Impact of nutritional status on morbidity in a population of geriatric rehabilitation patients.
D. Sullivan (1994)
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
M. Kojima (1999)
Nutrition and Physical Activity During and After Cancer Treatment: An American Cancer Society Guide for Informed Choices
C. Doyle (2003)
A Review of the Drug Treatment of Cachexia Associated with Cancer
B. Gagnon (2012)